Poziotinib Sustains High Response Rates Against Intractable Lung Cancer Mutation
September 05, 2018
September 05, 2018
HOUSTON, Texas, Sept. 5 -- The University of Texas MD Anderson Cancer Center issued the following news release:
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide high response rates among stage 4 non-small cell lung cancer patients with genetic mutations that have routinely defeated treatment.
Early results from a phase II clinical trial, reported in an abstract released today for the IASLC World Conference on Lung C . . .
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide high response rates among stage 4 non-small cell lung cancer patients with genetic mutations that have routinely defeated treatment.
Early results from a phase II clinical trial, reported in an abstract released today for the IASLC World Conference on Lung C . . .